Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world.
作者信息
Sharma Ashish, Kumar Nilesh, Parachuri Nikulaa, Singh Sonali, Bandello Francesco, Kuppermann Baruch D, Loewenstein Anat
机构信息
Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India.
Madhavi Netralaya, Ara, Bihar, India.
出版信息
Eye (Lond). 2021 May;35(5):1292-1294. doi: 10.1038/s41433-020-01227-w. Epub 2020 Oct 20.
Abstract
摘要
相似文献
1
Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world.
Eye (Lond). 2021 May;35(5):1292-1294. doi: 10.1038/s41433-020-01227-w. Epub 2020 Oct 20.
2
[Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolucizumab].
Ophthalmologe. 2022 Mar;119(3):296-299. doi: 10.1007/s00347-021-01341-4. Epub 2021 Feb 24.
3
Retinal vasculitis after intravitreal injection of brolucizumab.
Can J Ophthalmol. 2022 Apr;57(2):e40. doi: 10.1016/j.jcjo.2021.04.004. Epub 2021 May 7.
4
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
Ophthalmology. 2020 Oct;127(10):1345-1359. doi: 10.1016/j.ophtha.2020.04.017. Epub 2020 Apr 25.
5
Is This a 737 Max Moment for Brolucizumab?
Am J Ophthalmol. 2020 Aug;216:A7-A8. doi: 10.1016/j.ajo.2020.05.012. Epub 2020 May 25.
6
Retinal Vasculitis After Administration of Brolucizumab Resulting in Severe Loss of Visual Acuity.
JAMA Ophthalmol. 2020 Oct 1;138(10):1103-1104. doi: 10.1001/jamaophthalmol.2020.2810.
7
Association of Occlusive Retinal Vasculitis With Intravitreal Faricimab.
JAMA Ophthalmol. 2024 May 1;142(5):489-491. doi: 10.1001/jamaophthalmol.2024.0928.
8
Re: Monés et al.: Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER (Ophthalmology. 2021;128:1050-1059).
Ophthalmology. 2021 Sep;128(9):e47. doi: 10.1016/j.ophtha.2021.04.029. Epub 2021 May 28.
9
Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy.
Jpn J Ophthalmol. 2021 Mar;65(2):199-207. doi: 10.1007/s10384-021-00818-8. Epub 2021 Feb 5.
10
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Ophthalmology. 2021 Jul;128(7):1050-1059. doi: 10.1016/j.ophtha.2020.11.011. Epub 2020 Nov 15.
引用本文的文献
1
Real-world outcomes, including intraocular inflammation, after intravitreal brolucizumab for diabetic macular edema.
Jpn J Ophthalmol. 2025 Jun 12. doi: 10.1007/s10384-025-01226-y.
2
Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration.
Life (Basel). 2024 Jan 29;14(2):193. doi: 10.3390/life14020193.
3
Bioengineering of Antibody Fragments: Challenges and Opportunities.
Bioengineering (Basel). 2023 Jan 17;10(2):122. doi: 10.3390/bioengineering10020122.
4
HIF1A Knockout by Biallelic and Selection-Free CRISPR Gene Editing in Human Primary Endothelial Cells with Ribonucleoprotein Complexes.
Biomolecules. 2022 Dec 22;13(1):23. doi: 10.3390/biom13010023.
5
Progress on the application of growth factor-related drugs in ophthalmology.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022 Nov 25;51(5):626-633. doi: 10.3724/zdxbyxb-2022-0075.
6
A case of intraocular inflammation after intravitreal brolucizumab injection monitored by laser flare-cell photometer.
Am J Ophthalmol Case Rep. 2022 Oct 15;28:101727. doi: 10.1016/j.ajoc.2022.101727. eCollection 2022 Dec.
7
A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis in patients with neovascular age-related macular degeneration.
Indian J Ophthalmol. 2022 Aug;70(8):3008-3014. doi: 10.4103/ijo.IJO_2118_21.
8
Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting.
J Ophthalmol. 2022 Mar 25;2022:2659714. doi: 10.1155/2022/2659714. eCollection 2022.
9
Bilateral blindness after uneventful brolucizumab injection for macular degeneration.
BMC Ophthalmol. 2022 Feb 16;22(1):80. doi: 10.1186/s12886-022-02305-1.
10
Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration.
PLoS One. 2021 Dec 6;16(12):e0259879. doi: 10.1371/journal.pone.0259879. eCollection 2021.
本文引用的文献
1
Advanced Coats' disease treated with intravitreal brolucizumab combined with laser photocoagulation.
Am J Ophthalmol Case Rep. 2020 Jul 2;19:100815. doi: 10.1016/j.ajoc.2020.100815. eCollection 2020 Sep.
2
Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations.
Am J Ophthalmol Case Rep. 2020 Apr 2;18:100687. doi: 10.1016/j.ajoc.2020.100687. eCollection 2020 Jun.
3
Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration.
Am J Ophthalmol Case Rep. 2020 Mar 31;18:100680. doi: 10.1016/j.ajoc.2020.100680. eCollection 2020 Jun.
4
Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1.
J Clin Immunol. 2013 Oct;33(7):1192-203. doi: 10.1007/s10875-013-9915-0. Epub 2013 Jul 6.
5
Avastin doesn't blind people, people blind people.
Am J Ophthalmol. 2012 Feb;153(2):196-203.e1. doi: 10.1016/j.ajo.2011.11.023.
Zotero 插件